EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel Approaches to anti-EGFR Therapy

E V Dudkina, A I Nadyrova, S A Luginskaya, A S Kosnyrev, V V Ulyanova, O N Ilinskaya

Молекулярная биология / Molecular Biology · 2025 · 59 (6) · 909

DOI: 10.7868/s3034555325060034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Молекулярная биология / Molecular Biology, 2025. Verfasst von E V Dudkina und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 420008 Russia. Hauptthemen laut MEDLINE: ErbB Receptors, Neoplasms, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) is one of the most studied proteins in the world. A genuine interest in EGFR is related to its key role in the main conserved signalling pathways responsible for cell growth, survival, and proliferation. Dysregulation of these signalling pathways leads to malignant transformation, promotion of tumour progression, cell migration and invasion. In this regard, EGFR is considered as one of the main targets for anticancer drugs development. Despite several generations of novel anti-EGFR drugs have been successfully developed, acquisition of drug resistance, as well as the mutation status of downstream effector protein KRAS, significantly reduce tumour response to the therapy. This review focuses on the current approaches of anti-EGFR therapy. Here, we will describe drugs aimed at blocking EGFR-mediated signalling, such as monoclonal antibodies, tyrosine kinase inhibitors. Mechanisms of acquired resistance to anti-EGFR therapy will be reviewed, and combination treatment strategies will be proposed. Finally, we will discuss promising antitumor agents including immunotoxins and ribonucleases (RNases) of various origins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsNeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsAntineoplastic AgentsHumansSignal TransductionProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalImmunotoxins

Stichwörter der Autor:innen

EGFRbinasedrug resistanceepidermal growth factor receptormonoclonal antibodiesribonucleasestyrosine kinase inhibitors

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic AgentsProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalImmunotoxinsKRAS protein, human

Autor:innen und Institutionen

  • Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 420008 Russia.
  • alsu.nadyrova@yandex.ru.

Zitieren

APA

Dudkina, E. V., Nadyrova, A. I., Luginskaya, S. A., Kosnyrev, A. S., Ulyanova, V. V., & Ilinskaya, O. N. (2025). Novel Approaches to anti-EGFR Therapy. Молекулярная биология / Molecular Biology, 59(6), 909. https://doi.org/10.7868/s3034555325060034

Vancouver

Dudkina EV, Nadyrova AI, Luginskaya SA, Kosnyrev AS, Ulyanova VV, Ilinskaya ON. Novel Approaches to anti-EGFR Therapy. Молекулярная биология / Molecular Biology. 2025;59(6):909. doi:10.7868/s3034555325060034

BibTeX
@article{Dudkina2025,
  author = {Dudkina, E V and Nadyrova, A I and Luginskaya, S A and Kosnyrev, A S and Ulyanova, V V and Ilinskaya, O N},
  title = {Novel Approaches to anti-EGFR Therapy},
  journal = {Молекулярная биология / Molecular Biology},
  year = {2025},
  volume = {59},
  number = {6},
  pages = {909},
  doi = {10.7868/s3034555325060034}
}
Kostenlos starten →